VIR revenue surges 19582.5% YoY to $238.9M on $238.9M Astellas upfront; operating income swings positive

Filed August 5, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 6, 2025 · ~2 min read

Key Changes

• high

  Astellas collaboration closed with $240M upfront payment and $75M equity investment for VIR-5500 (PSMA-targeted TCE for prostate cancer); VIR eligible for up to $1.39B in future milestones plus tiered double-digit royalties on ex-U.S. sales and equal U.S. profit-sharing.

  Notes: Astellas collaboration verify on EDGAR →
• high

  Operating income swung from -$118.4M loss (Q2 2025) to $73.5M income (Q2 2026), driven by the $239.3M Astellas upfront payment recognized as license revenue; six-month operating loss narrowed from $258.0M to $58.8M.

  MD&A: Operating income YoY verify on EDGAR →
• high

  ECLIPSE 2 enrollment completed, finalizing the three-trial CHD registrational program; topline data from ECLIPSE 1 expected Q4 2026, ECLIPSE 2 and 3 data expected Q1 2027, positioning the company for potential regulatory filings in 2027.

  MD&A: ECLIPSE 2 enrollment verify on EDGAR →